Sandoz’s global biosimilars portfolio will help the company achieve overall low-single-digit turnover growth in the second half of 2020, CEO Richard Saynor has forecast, as their impact helped mitigate somewhat a significant COVID-19-inspired downturn in sales in the second quarter.
Biosimilars Will Lift Sandoz Following Q2 Sales Slump
Reversal Of COVID-19 Impact Hurts Top Line
Having benefited financially from the increased demand from the coronavirus pandemic in the first quarter, Sandoz saw a reversal of fortune in Q2 as sales fell by more than one-tenth as reported, as the company explained to Generics Bulletin.
More from Biosimilars
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
• By
Four key areas for policy reform were identified by industry association Medicines for Europe at its biosimilars conference in early April, as sector chair Isabell Remus set out the importance of removing barriers to biosimilar competition.
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.